Key result
Transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder was successful in 98% of patients, with no cases of erosion, late embolization, or death during mid-term follow-up.
Why the study?
Is transcatheter closure of secundum ASDs using the Amplatzer septal occluder safe and effective in pediatric and young adult patients?
Cohort (n=208)
No
Is transcatheter closure of secundum ASDs using the Amplatzer septal occluder safe and effective in pediatric and young adult patients?
Transcatheter closure of secundum ASDs using the Amplatzer septal occluder is safe and effective in children and young adults, with excellent mid-term outcomes and no major late complications when appropriate sizing is used.
Answers are grounded in this paper and cite their sources.
Supports mid-term safety of Amplatzer ASD closure in young patients; leaves open need for randomized trials versus surgery.
BACKGROUND: Transcatheter closure of atrial septal defects (ASDs) has become an alternative to open surgical procedures. The Amplatzer septal occluder (ASO) has been approved since 2005 in Japan, but there are still many concerns about adverse events, and information about outcomes and complications is limited. The objective of this study was to assess the immediate and mid-term outcomes of device closure of secundum ASDs. METHODS AND RESULTS: From August 2005 to July 2011, 208 consecutive patients with a significant secundum ASD underwent percutaneous closure with the ASO [72 males, 136 females; median age, 7.3 years (range, 3.3-21.9 years)]. Follow-up was available for 206 (99%) patients. Device closure was successful in 203 (98%) patients. Device embolization occurred in 1 case within 1h of device implantation, but the device was surgically retrieved without any neurological sequelae. During the follow-up period, complete closure was observed in 202 of 203 patients. There were no cases of erosions, late embolization, thrombus formation, or death. CONCLUSIONS: Transcatheter closure of ASDs using the ASO is safe and effective, with excellent results during mid-term follow-up. Appropriate patient selection and accurate device selection is mandatory to avoid serious complications.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2012) conducted a cohort in Secundum atrial septal defect (n=208). Amplatzer septal occluder (ASO) was evaluated on Successful device closure. Transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder was successful in 98% of patients, with no cases of erosion, late embolization, or death during mid-term follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: